You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

 Google Custom Search

Rilpivirine (Edurant,TMC278)


FDA Approves NNRTI Rilpivirine (Edurant, TMC278)
5-20-2011

Low Vitamin D Levels Less Likely with Rilpivirine than Efavirenz
3-18-2011

Evaluation Resumes for Gilead's Rilpivirine/Truvada Single-tablet Regimen
2-18-2011

FDA Declines New Drug Application for Rilpivirine/Truvada Combination Pill
1-28-2011

Gilead Submits Rilpivirine (TMC278) Single-tablet Regimen for FDA Approval
11/30/2010

Rilpivirine Failure Linked to High Viral Load and Poor Adherence
9/24/2010

Gilead Files for European Approval of Single-tablet Regimen Containing New NNRTI Rilpivirine
9/10/2010

New NNRTI Rilpivirine (TMC278) Shows Potent Antiviral Activity and Good Tolerability in Phase 3 Trials, FDA Application Submitted
7/26/2010

Pooled Week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomised, Phase III trials comparing TMC278 versus efavirenz in treatment-na´ve, HIV-1-infected patients

7/23/2010

Pharmacokinetic interaction study between TMC278, a next-generation NNRTI, and methadone
7/23/2010

Relative bioavailability of a concept paediatric formulation of TMC278, an investigational NNRTI
7/23/2010

Gilead Working on Once-daily Coformulation of Tibotec's NNRTI Rilpivirine (TMC278) plus Tenofovir/emtricitabine
4/24/2010

Experimental NNRTI Rilpivirine (TMC278) Shows Efficacy Comparable to Efavirenz (Sustiva) at 96 Weeks, but with Fewer Side Effects

12/08/2009

Depot Formulation of Rilpivirine (TMC278) May Offer Months of Sustained Anti-HIV Activity with a Single Injection
8/29/2008


Investigational Next-generation NNRTI Rilpivirine (TMC278) Demonstrates Potent Antiviral Activity at 96 Weeks in Treatment-naive Individuals
8/08/2008


Tibotec Opens Enrollment for 2 Phase III Trials of Experimental NNRTI Rilpivirine (TMC278) in Treatment-naive Patients
7/22/2008

Long-acting TMC278, a parenteral depot formulation delivering sustained NNRTI plasma concentrations in preclinical and clinical settings
2/20/2008





 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


FDA-approved HIV
and AIDS Treatments
Protease Inhibitors PIs
non Nucleoside Reverse
  
Transcriptase Inhibitors nNRTIs
Nucleoside / Nucleotide
  
Reverse Transcriptase Inhibitors NRTIs
Fixed-dose Combinations
Entry / Fusion Inhibitors EIs
Integrase Inhibitors

Experimental Treatments

HIV and AIDS
Articles by Topic
Adverse Events
Opportunistic Infections
Metabolic Complications
Lipodystrophy - Fat Redistribution
Treatment Guidelines
Women/Children